Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineZanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

In this multinational, phase 3, head-to-head trial (ALPINE), patients who received zanubrutinib — a Bruton’s tyrosine kinase (BTK) inhibitor with greater specificity– rather than the BTK inhibitor ibrutinib, had significantly longer progression-free survival in individuals with relapsed or refractory CLL or SLL, and zanubrutinib was linked to fewer cardiac side events.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form